Experimental vaccines against potentially pandemic and highly pathogenic avian influenza viruses

Future Virology

Volumn 8, Issue 1, 2013, Pages 25-41

  Mooney, Alaina J ^a   Tompkins, S Mark ^a  

^a UNIVERSITY OF GEORGIA   (United States)

Author keywords

HPAI; influenza; influenza A virus; live attenuated vaccine; pandemic; vaccine; virus vectors

Indexed keywords

ADENOVIRUS VECTOR; ALPHA VIRUS VECTOR; AS 03; AVIAN INFLUENZA VACCINE; BACULOVIRUS VECTOR; CONDITIONALLY REPLICATING ADENOVIRUS; CPG OLIGODEOXYNUCLEOTIDE; DNA VACCINE; IMMUNOLOGICAL ADJUVANT; IMMUNOMODULATING AGENT; INACTIVATED VACCINE; INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; ISCOM; LIVE VACCINE; MIFAMURTIDE; NONSEGMENTED NEGATIVE SENSE SINGLE STRANDED RNA VECTOR; PARAMYXOVIRUS VECTOR; POXVIRUS VECTOR; RECOMBINANT VACCINE; SUBUNIT VACCINE; TOLL LIKE RECEPTOR AGONIST; UNCLASSIFIED DRUG; VIRUS ANTIGEN; VIRUS LIKE PARTICLE VACCINE; VIRUS SIALIDASE; VIRUS VECTOR; VIRUS VECTORED VACCINE;

ANTIBODY RESPONSE; AVIAN INFLUENZA; CAUSE OF DEATH; CELLULAR IMMUNITY; CROSS REACTION; DRUG EFFICACY; DRUG SAFETY; GENE EXPRESSION; HUMAN; HUMORAL IMMUNITY; IMMUNOGENICITY; INFLUENZA A (H1N1); INFLUENZA A (H3N2); INFLUENZA A (H5N1); INFLUENZA VACCINATION; LICENSING; MODIFIED VACCINIA VIRUS ANKARA; NEWCASTLE DISEASE PARAMYXOVIRUS; NONHUMAN; PANDEMIC INFLUENZA; PRIORITY JOURNAL; REVERSE GENETICS; REVIEW; SEASONAL INFLUENZA; SIMIAN PARAINFLUENZA VIRUS 5; VACCINE PRODUCTION; VACCINIA VIRUS; VESICULAR STOMATITIS VIRUS;

AVIAN INFLUENZA VIRUS; INFLUENZA A VIRUS; ORTHOMYXOVIRIDAE;

EID: 84871532028     PISSN: 17460794     EISSN: 17460808     Source Type: Journal    
DOI: 10.2217/fvl.12.122     Document Type: Review

References (179)

1. Fiore AE, Uyeki TM, Broder K et al. Prevention and control of influenza with vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm. Rep. 59(RR 8), 1-62 (2010).
2. Taubenberger JK, Morens D. 1918 Influenza: The mother of all pandemics. Emerg. Infect. Dis. 12, 15-22 (2006).
3. Webster RG. The importance of animal influenza for human disease. Vaccine 20(Suppl. 2), S16-S20 (2002).
4. de Jong JC, Palache AM, Beyer WEP, Rimmelzwaan GF, Boon ACM, Osterhaus AD. Haemagglutination-inhibiting antibody to influenza virus. Dev. Biol. (Basel) 115, 63-73 (2003).
5. Smith DJ, Lapedes AS, de Jong JC et al. Mapping the antigenic and genetic evolution of influenza virus. Science 305(5682), 371-376 (2004).
6. Neumann G, Kawaoka Y. The first influenza pandemic of the new millennium. Influenza Other Respi. Viruses 5(3), 157-166 (2011).
7. US Department of Health and Human Services. An HHS Retrospective on the 2009 H1N1 Influenza Pandemic to Advance All Hazards Preparedness. US Department of Health and Human Services, Washington, DC, USA (2012).
8. Leroux-Roels I, Bernhard R, Gerard P, Drame M, Hanon E, Leroux-Roels G. Broad clade 2 cross-reactive immunity induced by an adjuvanted clade 1 rH5N1 pandemic influenza vaccine. PLoS One 3(2), e1665 (2008).
9. Baras B, Stittelaar KJ, Simon JH et al. Cross protection against lethal H5N1 challenge in ferrets with an adjuvanted pandemic influenza vaccine. PLoS One 3(1), e1401 (2008).
10. Benton KA, Misplon JA, Lo CY, Brutkiewicz RR, Prasad SA, Epstein SL. Heterosubtypic immunity to influenza A virus in mice lacking IgA, all Ig, NKT cells, or gamma delta T cells. J. Immunol. 166(12), 7437-7445 (2001).
11. Kreijtz JH, Bodewes R, van Amerongen G et al Primary influenza A virus infection induces cross-protective immunity against a lethal infection with a heterosubtypic virus strain in mice. Vaccine 25(4), 612-620 (2007).
12. Tompkins SM, Zhao Z-S, Lo C-Y et al. Matrix protein 2 vaccination and protection against influenza viruses, including subtype H5N1. Emerg. Infect. Dis. 13(3), 426-435 (2007).
13. Sandbulte MR, Jimenez GS, Boon ACM, Smith LR, Treanor JJ, Webby RJ. Cross-reactive neuraminidase antibodies afford partial protection against H5N1 in mice and are present in unexposed humans. PLoS Med. 4(2), e59 (2007).
14. Sylte MJ, Suarez DL. Influenza neuraminidase as a vaccine antigen. In: Vaccines for Pandemic Influenza. Compans RW, Orenstein WA (Eds). Springer, Germany, 227-241 (2009).
15. Bennink JR, Yewdell JW, Smith GL, Moss B. Anti-influenza virus cytotoxic T lymphocytes recognize the three viral polymerases and a nonstructural protein: Responsiveness to individual viral antigens is major histocompatibility complex controlled. J. Virol. 61(4), 1098-1102 (1987).
16. Steel J, Lowen AC, Wang TT et al. Influenza virus vaccine based on the conserved hemagglutinin stalk domain. MBio. 1(1), e00018-10 (2010).
17. Matthews J. Egg-based production of influenza vaccine: 30 years of commercial experience. The Bridge 36, 17-24 (2006).
18. Stohr K, Bucher D, Colgate T, Wood J. Influenza virus surveillance, vaccine strain selection, and manufacture. Methods Mol. Biol. 865, 147-162 (2012).
19. Montomoli E, Khadang B, Piccirella S et al. Cell culture-derived influenza vaccines from Vero cells: A new horizon for vaccine production. Expert Rev. Vaccines 11(5), 587-594 (2012).
20. Pandey A, Singh N, Sambhara S, Mittal SK. Egg-independent vaccine strategies for highly pathogenic H5N1 influenza viruses. Hum. Vaccin. 6(2), 178-188 (2010).
21. Takada A, Kuboki N, Okazaki K et al. Avirulent avian influenza virus as a vaccine strain against a potential human pandemic. J. Virol. 73(10), 8303-8307 (1999).
22. Treanor JJ, Campbell JD, Zangwill KM, Rowe T, Wolff M. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N. Engl. J. Med. 354(13), 1343-1351 (2006).
23. Horimoto T, Kawaoka Y. Reverse genetics provides direct evidence for a correlation of hemagglutinin cleavability and virulence of an avian influenza A virus. J. Virol. 68(5), 3120-3128 (1994).
24. Barrett PN, Mundt W, Kistner O, Howard MK. Vero cell platform in vaccine production: Moving towards cell culture-based viral vaccines. Expert Rev. Vaccines 8(5), 607-618 (2009).
25. Horimoto T, Kawaoka Y. Strategies for developing vaccines against H5N1 influenza A viruses. Trends Mol. Med. 12(11), 506-514 (2006).
26. Tseng Y-F, Hu AY-C, Huang M-L et al. Adaptation of high-growth influenza h5n1 vaccine virus in vero cells: Implications for pandemic preparedness. PLoS One 6(10), e24057 (2011).
27. Karron RA, Talaat K, Luke C et al. Evaluation of two live attenuated cold-adapted H5N1 influenza virus vaccines in healthy adults. Vaccine 27(36), 4953-4960 (2009).
28. Banzhoff A, Pellegrini M, Del Giudice G, Fragapane E, Groth N, Podda A. MF59- adjuvanted vaccines for seasonal and pandemic influenza prophylaxis. Influenza Other Respi. Viruses 2(6), 243-249 (2008).
29. Leroux-Roels I, Roman F, Forgus S et al. Priming with AS03A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: An open non-randomised extension of a double-blind randomized primary study. Vaccine 28(3), 849-857 (2010).
30. Bresson JL, Perronne C, Launay O et al. Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: Phase I randomised trial. Lancet 367(9523), 1657-1664 (2006).
31. Rimmelzwaan GF, Osterhaus AD. ISCOMs: Materials, preparation, antigen delivery and immune response. In: Antigen Delivery Systems. Gander B, Merkle H, Corradin G (Eds). Harwood Academic Publishers, UK, 123-138 (1997).
32. Rimmelzwaan GF, Osterhaus AD. Influenza vaccines: New developments. Curr. Opin. Pharmacol. 1, 491-496 (2001).
33. Vogel F, Hem S. Immunologic adjuvants. In: Vaccines. Sanders Elsevier, The Netherlands, 59-81 (2008).
34. Cox MM, Hollister Jr. FluBlok, a next generation influenza vaccine manufactured in insect cells. Biologicals 37(3), 182-189 (2009).
35. Treanor JJ, El Sahly H, King J et al. Protective efficacy of a trivalent recombinant hemagglutinin protein vaccine (FluBlok(R)) against influenza in healthy adults: A randomized, placebo-controlled trial. Vaccine 29(44), 7733-7739 (2011).
36. Baxter R, Patriarca PA, Ensor K, Izikson R, Goldenthal KL, Cox MM. Evaluation of the safety, reactogenicity and immunogenicity of FluBlok(R) trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy adults 50-64 years of age. Vaccine 29(12), 2272-2278 (2011).
37. King JC Jr, Cox MM, Reisinger K, Hedrick J, Graham I, Patriarca P. Evaluation of the safety, reactogenicity and immunogenicity of FluBlok trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy children aged 6-59 months. Vaccine 27(47), 6589-6594 (2009).
38. Kang SM, Pushko P, Bright R A, Smith G, Compans RW. Influenza virus-like particles as pandemic vaccines. Curr. Top. Microbiol. Immunol. 333, 269-289 (2009).
39. Mahmood K, Bright R A, Mytle N et al. H5N1 VLP vaccine induced protection in ferrets against lethal challenge with highly pathogenic H5N1 influenza viruses. Vaccine. 26(42), 5393-5399 (2008).
40. Song JM, Hossain J, Yoo DG et al. Protective immunity against H5N1 influenza virus by a single dose vaccination with virus-like particles. Virology 405(1), 165-175 (2010).
41. D'Aoust M-A, Lavoie P-O, Couture MMJ et al. Influenza virus-like particles produced by transient expression in Nicotiana benthamiana induce a protective immune response against a lethal viral challenge in mice. Plant Biotechnol. J. 6(9), 930-940 (2008).
42. Kim JH, Jacob J. DNA vaccines against influenza viruses. Curr. Top. Microbiol. Immunol. 333, 197-210 (2009).
43. Krieg AM. CpG motifs in bacterial DNA and their immune effects. Annu. Rev. Immunol. 20, 709-760 (2002).
44. Fu TM, Ulmer JB, Caulfield MJ et al. Priming of cytotoxic T lymphocytes by DNA vaccines: Requirement for professional antigen presenting cells and evidence for antigen transfer from myocytes. Mol. Med. 3(6), 362-371 (1997).
45. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 392(6673), 245-252 (1998).
46. Kodihalli S, Goto H, Kobasa DL, Krauss S, Kawaoka Y, Webster RG. DNA vaccine encoding hemagglutinin provides protective immunity against H5N1 influenza virus infection in mice. J. Virol. 73(3), 2094-2098 (1999).
47. Laddy DJ, Yan J, Kutzler M et al. Heterosubtypic protection against pathogenic human and avian influenza viruses via in vivo electroporation of synthetic consensus DNA antigens. PLoS One 3(6), e2517 (2008).
48. Epstein SL, Tumpey T, Misplon JA et al. DNA vaccine expressing conserved influenza virus proteins protective against H5N1 challenge infection in mice. Emerg. Infect. Dis. 8(8), 796-801 (2002).
49. Smith LR, Wloch MK, Ye M et al. Phase I clinical trials of the safety and immunogenicity of adjuvanted plasmid DNA vaccines encoding influenza A virus H5 hemagglutinin. Vaccine 28(13), 2565-2572 (2010).
50. Liu MA. DNA vaccines: An historical perspective and view to the future. Immunol. Rev. 239(1), 62-84 (2011).
51. Bråve A, Ljungberg K, Wahren B, Liu MA. Vaccine delivery methods using viral vectors. Mol. Pharm. 4(1), 18-32 (2006).
52. Ledgerwood JE, Wei CJ, Hu Z et al. DNA priming and influenza vaccine immunogenicity: Two Phase 1 open label randomised clinical trials. Lancet Infect. Dis. 11(12), 916-924 (2011).
53. Draper SJ, Heeney JL. Viruses as vaccine vectors for infectious diseases and cancer. Nat. Rev. Micro. 8(1), 62-73 (2010).
54. Suryanarayana VVS, Chattopadhyay D, Shaila MS. Non-segmented negative sense RNA viruses as vectors for vaccine development. Curr. Sci. 98(3), 379-391 (2010).
55. Osterhaus AD Pre- or post-pandemic influenza vaccine? Vaccine 25(27), 4983-4984 (2007).
56. Patterson L, Peng B, Nan X, Robert-Guroff M. Live adenovirus recombinants as vaccine vectors. In: New Generation Vaccines. Levine M, Kaper J, Rappuoli R, Liu M, Good M (Eds). Marcel Dekker, NY, USA, 325-335 (2004).
57. Hoelscher MA, Jayashankar L, Garg S et al. New pre-pandemic influenza vaccines: An egg- and adjuvant-independent human adenoviral vector strategy induces long-lasting protective immune responses in mice. Clin. Pharm. Ther. 82(6), 665-671 (2007).
58. Wei C-J, Boyington JC, McTamney PM et al. Induction of broadly neutralizing H1N1 influenza antibodies by vaccination. Science 329(5995), 1060-1064 (2010).
59. Van Kampen KR, Shi Z, Gao P et al. Safety and immunogenicity of adenovirus-vectored nasal and epicutaneous influenza vaccines in humans. Vaccine 23(8), 1029-1036 (2005).
60. Hoelscher MA, Garg S, Bangari DS et al. Development of adenoviral-vector-based pandemic influenza vaccine against antigenically distinct human H5N1 strains in mice. Lancet 367(9509), 475-481 (2006).
61. Toro H, Tang DC, Suarez DL, Sylte MJ, Pfeiffer J, Van Kampen KR. Protective avian influenza in ovo vaccination with non-replicating human adenovirus vector. Vaccine 25(15), 2886-2891 (2007).
62. Gao W, Soloff AC, Lu X et al. Protection of mice and poultry from lethal H5N1 avian influenza virus through adenovirus-based immunization. J. Virol. 80(4), 1959-1964 (2006).
63. Epstein SL, Kong W-p, Misplon JA et al. Protection against multiple influenza A subtypes by vaccination with highly conserved nucleoprotein. Vaccine 23(46-47), 5404-5410 (2005).
64. Roy S, Kobinger G, Lin J et al. Partial protection against H5N1 influenza in mice with a single dose of a chimpanzee adenovirus vector expressing nucleoprotein. Vaccine 25(39-40), 6845-6851 (2007).
65. Soboleski MR, Gabbard JD, Price GE et al. Cold-adapted influenza and recombinant adenovirus vaccines induce cross-protective immunity against pH1N1 challenge in mice. PLoS One 6(7), e21937 (2011).
66. Hoelscher MA, Singh N, Garg S et al. A broadly protective vaccine against globally dispersed clade 1 and clade 2 H5N1 influenza viruses. J. Infect. Dis. 197(8), 1185-1188 (2008).
67. Holman DH, Wang D, Raja NU et al. Multi-antigen vaccines based on complex adenovirus vectors induce protective immune responses against H5N1 avian influenza viruses. Vaccine 26(21), 2627-2639 (2008).
68. Marjorie R-G. Replicating and non-replicating viral vectors for vaccine development. Curr. Opin. Biotechnol. 18(6), 546-556 (2007).
69. Lubeck MD, Davis AR, Chengalvala M et al. Immunogenicity and efficacy testing in chimpanzees of an oral hepatitis B vaccine based on live recombinant adenovirus. Proc. Natl Acad. Sci. USA 86(17), 6763-6767 (1989).
70. Gao W, Tamin A, Soloff A et al. Effects of a SARS-associated coronavirus vaccine in monkeys. Lancet 362(9399), 1895-1896 (2003).
71. Wang D, Raja NU, Trubey CM et al. Development of a cAdVax-based bivalent ebola virus vaccine that induces immune responses against both the Sudan and Zaire species of Ebola virus. J. Virol. 80(6), 2738-2746 (2006).
72. Wang D, Schmaljohn AL, Raja NU et al. De novo syntheses of Marburg virus antigens from adenovirus vectors induce potent humoral and cellular immune responses. Vaccine 24(15), 2975-2986 (2006).
73. Schepp-Berglind J, Luo M, Wang D et al. Complex adenovirus-mediated expression of West Nile virus C, PreM, E, and NS1 proteins induces both humoral and cellular immune responses. Clin. Vaccine Immunol. 14(9), 1117-1126 (2007).
74. Holman DH, Wang D, Raviprakash K et al. Two complex, adenovirus-based vaccines that together induce immune responses to all four dengue virus serotypes. Clin. Vaccine Immunol. 14(2), 182-189 (2007).
75. Bonnet MC, Tartaglia J, Verdier F et al. Recombinant viruses as a tool for therapeutic vaccination against human cancers. Immunol. Lett. 74(1), 11-25 (2000).
76. Doolan DL, Croyle MA, Patel A et al. Nasal delivery of an adenovirus-based vaccine bypasses pre-existing immunity to the vaccine carrier and improves the immune response in mice. PLoS One 3(10), e3548 (2008).
77. Patel A, Tikoo S, Kobinger G. A porcine adenovirus with low human seroprevalence is a promising alternative vaccine vector to human adenovirus 5 in an H5N1 virus disease model. PLoS One 5(12), 1-11 (2010).
78. Thorner AR, Lemckert AAC, Goudsmit J et al. Immunogenicity of heterologous recombinant adenovirus primeYboost vaccine regimens is enhanced by circumventing vector cross-reactivity. J. Virol. 80(24), 12009-12016 (2006).
79. Singh N, Pandey A, Jayashankar L, Mittal SK. Bovine adenoviral vector-based H5N1 influenza vaccine overcomes exceptionally high levels of pre-existing immunity against human adenovirus. Mol. Ther. 16(5), 965-971 (2008).
80. Drexler I, Heller K, Wahren B, Erfle V, Sutter G. Highly attenuated modified vaccinia virus Ankara replicates in baby hamster kidney cells, a potential host for virus propagation, but not in various human transformed and primary cells. J. Gen. Virol. 79 (Pt 2), 347-352 (1998).
81. Sutter G, Wyatt LS, Foley PL, Bennink JR, Moss B. A recombinant vector derived from the host range-restricted and highly attenuated MVA strain of vaccinia virus stimulates protective immunity in mice to influenza virus. Vaccine 12(11), 1032-1040 (1994).
82. Kreijtz JHCM, Suezer Y, van Amerongen G et al. Recombinant modified vaccinia virus Ankara-based vaccine induces protective immunity in mice against infection with influenza virus H5N1. J. Infect. Dis. 195(11), 1598-1606 (2007).
83. Kreijtz JHCM, Suezer Y, de Mutsert G et al. MVA-based H5N1 vaccine affords cross-clade protection in mice against influenza A/H5N1 viruses at low doses and after single immunization. PLoS One 4(11), e7790 (2009).
84. Poon LLM, Leung YHC, Nicholls JM et al. Vaccinia virus-based multivalent H5N1 avian influenza vaccines adjuvanted with IL-15 confer sterile cross-clade protection in mice. J. Immunol. 182(5), 3063-3071 (2009).
85. Berthoud TK, Hamill M, Lillie PJ et al. Potent CD8+ T-cell immunogenicity in humans of a novel heterosubtypic influenza A vaccine, MVA-NP+M1. Clin. Infect. Dis. 52(1), 1-7 (2011).
86. Sutter G, Staib C. Vaccinia vectors as candidate vaccines: The development of modified vaccinia virus Ankara for antigen delivery. Curr. Drug Targets Infect. Disord. 3(3), 263-271 (2003).
87. McShane H, Behboudi S, Goonetilleke N, Brookes R, Hill A. Protective immunity against Mycobacterium tuberculosis induced by dendritic cells pulsed with both CD8+- and CD4+-T-cell epitopes from antigen 85A. Infect. Immun. 70, 1623-1626 (2002).
88. Acres B, Bonnefoy J-Y. Clinical development of MVA-based therapeutic cancer vaccines. Expert Rev. Vaccines 7(7), 889-893 (2008).
89. Albrecht M, Suezer Y, Staib C, Sutter G, Vieths S, Reese G. Vaccination with a modified vaccinia virus Ankara-based vaccine protects mice from allergic sensitization. J. Gene Med. 10(12), 1324-1333 (2008).
90. Souza AP, Haut L, Reyes-Sandoval A, Pinto AR. Recombinant viruses as vaccines against viral diseases. Braz. J. Med. Biol. Res. 38(4), 509-522 (2005).
91. Brandau DT, Jones LS, Wiethoff CM, Rexroad J, Middaugh CR. Thermal stability of vaccines. J. Pharm. Sci. 92(2), 218-231 (2003).
92. Alcock R, Cottingham MG, Rollier CS et al. Long-term thermostabilization of live poxviral and adenoviral vaccine vectors at supraphysiological temperatures in carbohydrate glass. Sci. Transl. Med. 2(19), 19ra12 (2010).
93. Stittelaar KJ, Kuiken T, de Swart RL et al. Safety of modified vaccinia virus Ankara (MVA) in immune-suppressed macaques. Vaccine 19(27), 3700-3709 (2001).
94. Wang Z, La Rosa C, Maas R et al. Recombinant modified vaccinia virus ankara expressing a soluble form of glycoprotein b causes durable immunity and neutralizing antibodies against multiple strains of human cytomegalovirus. J. Virol. 78(8), 3965-3976 (2004).
95. Yang Zy, Wyatt LS, Kong Wp, Moodie Z, Moss B, Nabel GJ. Overcoming immunity to a viral vaccine by DNA priming before vector boosting. J. Virol. 77(1), 799-803 (2003).
96. Drexler I, Staib C, Sutter G. Modified vaccinia virus Ankara as antigen delivery system: how can we best use its potential? Curr. Opin. Biotechnol. 15(6), 506-512 (2004).
97. Belyakov IM, Moss B, Strober W, Berzofsky JA. Mucosal vaccination overcomes the barrier to recombinant vaccinia immunization caused by preexisting poxvirus immunity. Proc. Natl Acad. Sci. USA 96(8), 4512-4517 (1999).
98. Schlesinger S. Alphavirus expression systems Y promises and problems. ASM News 65, 688-695 (1999).
99. Davis NL, West A, Reap E et al. Alphavirus replicon particles as candidate HIV vaccines. IUBMB Life 53(4-5), 209-211 (2002).
100. Strauss JH, Strauss EG. The alphaviruses: Gene expression, replication, and evolution. Microbiol. Rev. 58(3), 491-562 (1994).
101. Berglund P, Fleeton MN, Smerdou C, Liljeström P. Immunization with recombinant Semliki Forest virus induces protection against influenza challenge in mice. Vaccine 17(5), 497-507 (1999).
102. Schultz-Cherry S, Dybing JK, Davis NL et al. Influenza virus (A/HK/156/97) hemagglutinin expressed by an alphavirus replicon system protects chickens against lethal infection with Hong Kong-origin H5N1 viruses. Virology 278(1), 55-59 (2000).
103. Sylte MJ, Hubby B, Suarez DL. Influenza neuraminidase antibodies provide partial protection for chickens against high pathogenic avian influenza infection. Vaccine 25(19), 3763-3772 (2007).
104. Erdman MM, Kamrud KI, Harris DL, Smith J. Alphavirus replicon particle vaccines developed for use in humans induce high levels of antibodies to influenza virus hemagglutinin in swine: Proof of concept. Vaccine 28(3), 594-596 (2010).
105. Defang GN, Khetawat D, Broder CC, Quinnan Jr GV. Induction of neutralizing antibodies to Hendra and Nipah glycoproteins using a Venezuelan equine encephalitis virus in vivo expression system. Vaccine 29(2), 212-220 (2010).
106. Lundstrom K. Alphavirus vectors for vaccine production and gene therapy. Expert Rev. Vaccines 2(3), 445-459 (2003).
107. Barr JN, Fearns R. How RNA viruses maintain their genome integrity. J. General Virol. 91(6), 1373-1387 (2010).
108. Madhan S, Prabakaran M, Kwang J. Baculovirus as vaccine vectors. Curr. Gene Ther. 10(3), 201-213 (2010).
109. Volkman LE, Goldsmith PA. In vitro survey of Autographa californica nuclear polyhedrosis virus interaction with nontarget vertebrate host cells. Appl. Environ. Microbiol. 45(3), 1085-1093 (1983).
110. Barsoum J, Brown R, McKee M, Boyce FM. Efficient transduction of mammalian cells by a recombinant baculovirus having the vesicular stomatitis virus G glycoprotein. Hum. Gene. Ther. 8(17), 2011-2018 (1997).
111. Wu Q, Fang L, Wu X et al. A pseudotype baculovirus-mediated vaccine confers protective immunity against lethal challenge with H5N1 avian influenza virus in mice and chickens. Mol. Immunol. 46(11-12), 2210-2217 (2009).
112. Yang D-G, Chung Y-C, Lai Y-K, Lai C-W, Liu H-J, Hu Y-C. Avian influenza virus hemagglutinin display on baculovirus envelope: Cytoplasmic domain affects virus properties and vaccine potential. Mol. Ther. 15(5), 989-996 (2007).
113. Chen C-Y, Liu H-J, Tsai C-P et al. Baculovirus as an avian influenza vaccine vector: Differential immune responses elicited by different vector forms. Vaccine 28(48), 7644-7651 (2010).
114. Tang X-C, Lu H-R, Ross TM. Hemagglutinin displayed baculovirus protects against highly pathogenic influenza. Vaccine 28(42), 6821-6831 (2010).
115. Pekosz A, He B, Lamb RA. Reverse genetics of negative-strand RNA viruses: Closing the circle. Proc. Natl Acad. Sci. 96, 8804-8806 (1999).
116. He B, Paterson RG, Ward CD, Lamb RA. Recovery of infectious SV5 from cloned DNA and expression of a foreign gene. Virology 237, 249-260 (1997).
117. Lyles DS, Rupprecht CE. Rhabdoviridae. In: Fields Virology. Knipe DM, Howley PM (Eds). Lippincott Williams and Wilkins, PA, USA (2007).
118. Quiroz E, Moreno N, Peralta PH, Tesh RB A human case of encephalitis associated with vesicular stomatitis virus (Indiana serotype) infection. Am. J. Trop. Med. Hyg. 39(3), 312-314 (1988).
119. Haglund K, Forman J, Krausslich HG, Rose JK. Expression of human immunodeficiency virus type 1 Gag protein precursor and envelope proteins from a vesicular stomatitis virus recombinant: high-level production of virus-like particles containing HIV envelope. Virology 268(1), 112-121 (2000).
120. Schnell MJ, Buonocore L, Kretzschmar E, Johnson E, Rose JK. Foreign glycoproteins expressed from recombinant vesicular stomatitis viruses are incorporated efficiently into virus particles. Proc. Natl Acad. Sci. USA 93(21), 11359-11365 (1996).
121. Schlegel R, Tralka TS, Willingham MC, Pastan I Inhibition of VSV binding and infectivity by phosphatidylserine: Is phosphatidylserine a VSV-binding site? Cell 32(2), 639-646 (1983).
122. Coil DA, Miller AD. Phosphatidylserine is not the cell surface receptor for vesicular stomatitis virus. J. Virol. 78(20), 10920-10926 (2004).
123. Lund JM, Alexopoulou L, Sato A et al. Recognition of single-stranded RNA viruses by Toll-like receptor 7. Proc. Natl Acad. Sci. USA 101(15), 5598-5603 (2004).
124. Roberts A, Buonocore L, Price R, Forman J, Rose JK. Attenuated vesicular stomatitis viruses as vaccine vectors. J. Virol. 73(5), 3723-3732 (1999).
125. Barefoot BE, Athearn K, Sample CJ, Ramsburg EA. Intramuscular immunization with a vesicular stomatitis virus recombinant expressing the influenza hemagglutinin provides post-exposure protection against lethal influenza challenge. Vaccine 28(1), 79-89 (2009).
126. Barefoot BE, Sample CJ, Ramsburg EA. Recombinant vesicular stomatitis virus expressing influenza nucleoprotein induces CD8 T-cell responses that enhance antibody-mediated protection after lethal challenge with influenza virus. Clin. Vaccine Immunol. 16(4), 488-498 (2009).
127. Schwartz J, Buonocore L, Roberts A et al. Vesicular stomatitis virus vectors expressing avian influenza H5 HA induce cross-neutralizing antibodies and long-term protection. Virology 366(1), 166-173 (2007).
128. Villarreal LP, Breindl M, Holland JJ. Determination of molar ratios of vesicular stomatitis virus induced RNA species in BHK21 cells. Biochemistry 15(8), 1663-1667 (1976).
129. Schwartz JA, Buonocore L, Suguitan AL et al. Potent vesicular stomatitis virus-based avian influenza vaccines provide long-term sterilizing immunity against heterologous challenge. J. Virol. 84(9), 4611-4618 (2010).
130. Schwartz JA, Buonocore L, Suguitan A Jr et al. Vesicular stomatitis virus-based H5N1 avian influenza vaccines induce potent cross-clade neutralizing antibodies in rhesus macaques. J. Virol. 85(9), 4602-4605 (2011).
131. Kalhoro NH, Veits J, Rautenschlein S, Zimmer G. A recombinant vesicular stomatitis virus replicon vaccine protects chickens from highly pathogenic avian influenza virus (H7N1). Vaccine 27(8), 1174-1183 (2009).
132. Clarke D, Cooper D, Egan M, Hendry R, Parks C, Udem S. Recombinant vesicular stomatitis virus as an HIV-1 vaccine vector. Springer Semin. Immunopathol. 28(3), 239-253 (2006).
133. Rose NF, Marx PA, Luckay A et al. An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants. Cell 106(5), 539-549 (2001).
134. van den Pol AN, Dalton KP, Rose JK. Relative neurotropism of a recombinant rhabdovirus expressing a green fluorescent envelope glycoprotein. J. Virol. 76(3), 1309-1327 (2002).
135. Johnson JE, Nasar F, Coleman JW et al. Neurovirulence properties of recombinant vesicular stomatitis virus vectors in non-human primates. Virology 360(1), 36-49 (2007).
136. Geisbert TW, Daddario-Dicaprio KM, Lewis MG et al. Vesicular stomatitis virus-based ebola vaccine is well-tolerated and protects immunocompromised nonhuman primates. PLoS Pathog. 4(11), e1000225 (2008).
137. Kapadia SU, Simon ID, Rose JK. SARS vaccine based on a replication-defective recombinant vesicular stomatitis virus is more potent than one based on a replication-competent vector. Virology 376(1), 165-172 (2008).
138. Lorin C, Mollet L, Delebecque F et al. A single injection of recombinant measles virus vaccines expressing human immunodeficiency virus (HIV) type 1 clade B envelope glycoproteins induces neutralizing antibodies and cellular immune responses to HIV. J. Virol. 78(1), 146-157 (2004).
139. Bukreyev AA, DiNapoli JM, Yang L, Murphy BR, Collins PL. Mucosal parainfluenza virus-vectored vaccine against Ebola virus replicates in the respiratory tract of vector-immune monkeys and is immunogenic. Virology 399(2), 290-298 (2010).
140. Schmidt AC, Wenzke DR, McAuliffe JM et al. Mucosal immunization of rhesus monkeys against respiratory syncytial virus subgroups A and B and human parainfluenza virus type 3 by using a live cDNA-derived vaccine based on a host range-attenuated bovine parainfluenza virus type 3 vector backbone. J. Virol. 76(3), 1089-1099 (2002).
141. Hanson RP. Newcastle Disease. Iowa State University Press, IO, USA (1978).
142. Bukreyev A, Huang Z, Yang L et al. Recombinant newcastle disease virus expressing a foreign viral antigen is attenuated and highly immunogenic in primates. J. Virol. 79(21), 13275-13284 (2005).
143. Bukreyev A, Collins PL. Newcastle disease virus as a vaccine vector for humans. Curr. Opin. Mol. Ther. 10(1), 46-55 (2008).
144. Nakaya T, Cros J, Park MS et al. Recombinant Newcastle disease virus as a vaccine vector. J. Virol. 75(23), 11868-11873 (2001).
145. Swayne DE, Suarez DL, Schultz-Cherry S et al. Recombinant paramyxovirus type 1-avian influenza-H7 virus as a vaccine for protection of chickens against influenza and Newcastle disease. Avian Dis. 47(3 Suppl.), 1047-1050 (2003).
146. Veits J, Wiesner D, Fuchs W et al. Newcastle disease virus expressing H5 hemagglutinin gene protects chickens against Newcastle disease and avian influenza. Proc. Natl Acad. Sci. USA 103(21), 8197-8202 (2006).
147. Park MS, Steel J, Garcia-Sastre A, Swayne D, Palese P. Engineered viral vaccine constructs with dual specificity: Avian influenza and Newcastle disease. Proc. Natl Acad. Sci. USA 103(21), 8203-8208 (2006).
148. DiNapoli JM, Yang L, Suguitan A et al. Immunization of primates with a Newcastle disease virus-vectored vaccine via the respiratory tract induces a high titer of serum neutralizing antibodies against highly pathogenic avian influenza virus. J. Virol. 81(21), 11560-11568 (2007).
149. DiNapoli JM, Nayak B, Yang L et al. Newcastle disease virus-vectored vaccines expressing the hemagglutinin or neuraminidase protein of H5N1 highly pathogenic avian influenza virus protect against virus challenge in monkeys. J. Virol. 84(3), 1489-1503 (2010).
150. Martinez-Sobrido L, Gitiban N, Fernandez- Sesma A et al. Protection against respiratory syncytial virus by a recombinant newcastle disease virus vector. J. Virology 80(3), 1130-1139 (2006).
151. Nayak B, Kumar S, DiNapoli JM et al. Contributions of the avian influenza virus HA, NA, and M2 surface proteins to the induction of neutralizing antibodies and protective immunity. J. Virology 84(5), 2408-2420 (2009).
152. DiNapoli JM, Kotelkin A, Yang L et al. Newcastle disease virus, a host range-restricted virus, as a vaccine vector for intranasal immunization against emerging pathogens. Proc. Natl Acad. Sci. USA 104(23), 9788-9793 (2007).
153. DiNapoli JM, Yang L, Samal SK, Murphy BR, Collins PL, Bukreyev A. Respiratory tract immunization of non-human primates with a Newcastle disease virus-vectored vaccine candidate against Ebola virus elicits a neutralizing antibody response. Vaccine 29(1), 17-25 (2010).
154. Vigil A, Martinez O, Chua MA, Garcia- Sastre A. Recombinant Newcastle disease virus as a vaccine vector for cancer therapy. Mol. Ther. 16(11), 1883-1890 (2008).
155. Choppin PW. Multiplication of a myxovirus (SV5) with minimal cytopathic effects and without interference. Virology 23, 224-233 (1964).
156. Chatziandreou N, Stock D, Young J et al. Relationships and host range of human, canine, simian and porcine isolates of simian virus 5 (parainfluenza virus 5). J. Gen. Virol. 85(10), 3007-3016 (2004).
157. Kontor EJ, Wegrzyn RJ, Goodnow RA. Canine infectious tracheobronchitis: Effects of an intranasal live canine parainfluenza- Bordetella bronchiseptica vaccine on viral shedding and clinical tracheobronchitis (kennel cough). Am. J. Vet. Res. 42(10), 1694-1698 (1981).
158. Lamb RA, Parks GD. Paramyxoviridae: The viruses and their replication. In: Fields Virology. Howley DM, Knipe BN (Eds). Lippincott-Raven, PA, USA, 1449-1496 (2007).
159. Zhang L, Collins PL, Lamb RA, Pickles RJ. Comparison of differing cytopathic effects in human airway epithelium of parainfluenza virus 5 (W3A), parainfluenza virus type 3, and respiratory syncytial virus. Virology 421(1), 67-77 (2011).
160. He B, Paterson RG, Ward CD, Lamb RA. Recovery of infectious SV5 from cloned DNA and expression of a foreign gene. Virology 237(2), 249-260 (1997).
161. Karron RA, Collins PL. Parainfluenza viruses. In: Fields Virology. Knipe DM, Howley PM (Eds.) Lippincott Williams and Wilkins, Philadelphia, PA, USA, 1497-1526 (2007).
162. Tompkins SM, Lin Y, Leser GP et al. Recombinant parainfluenza virus 5 (PIV5) expressing the influenza A virus hemagglutinin provides immunity in mice to influenza A virus challenge. Virology 362(1), 139-150 (2007).
163. Li Z, Mooney A, Gabbard JD et al. Recombinant parainfluenza virus 5 expressing HA of influenza A virus H5N1 protected mice against lethal high pathogenic avian influenza H5N1 challenge. J. Virol. doi:10.1128/JVI.02321-12 (2012) (Epub ahead of print).
164. Mooney AJ, Li Z, Gabbard JD, He B, Tompkins SM. Recombinant PIV5 vaccine encoding the influenza hemagglutinin protects against H5N1 highly pathogenic avian influenza virus infection following intranasal or intramuscular vaccination of BALB/c mice. J. Virol. doi:10.1128/ JVI.02330-12 (2012) (Epub ahead of print).
165. Clark KM, Johnson JB, Kock ND, Mizel SB, Parks GD. Parainfluenza virus 5-based vaccine vectors expressing vaccinia virus (VACV) antigens provide long-term protection in mice from lethal intranasal VACV challenge. Virology 419, 97-106 (2011).
166. Young DF, Randall RE, Hoyle JA, Souberbielle BE. Clearance of a persistent paramyxovirus infection is mediated by cellular immune responses but not by serum-neutralizing antibody. J. Virol. 64(11), 5403-5411 (1990).
167. Johnson JB, Capraro GA, Parks GD. Differential mechanisms of complement-mediated neutralization of the closely related paramyxoviruses simian virus 5 and mumps virus. Virology 376(1), 112-123 (2008).
168. Capraro GA, Johnson JB, Kock ND, Parks GD. Virus growth and antibody responses following respiratory tract infection of ferrets and mice with WT and P/V mutants of the paramyxovirus Simian virus 5. Virology 376(2), 416-428 (2008).
169. Hsiung GD. Parainfluenza-5 virus. Infection of man and animal. Prog. Med. Virol. 14, 241-274 (1972).
170. Chen D, Kristensen D. Opportunities and challenges of developing thermostable vaccines. Expert Rev. Vaccines 8(5), 547-557 (2009).
171. Baylor NW, Houn F. Considerations for licensure of influenza vaccines with pandemic and prepandemic indications. Curr. Top. Microbiol. Immunol. 333, 453-470 (2009).
172. Broadbent AJ, Subbarao K. Influenza virus vaccines: Lessons from the 2009 H1N1 pandemic. Curr. Opin. Virol. 1(4), 254-262 (2011).
173. Lasaro MO, Ertl HCJ. New insights on adenovirus as vaccine vectors. Mol. Ther. 17(8), 1333-1339 (2009).
174. Woodland DL. Jump-starting the immune system: PrimeYboosting comes of age. Trends Immunol. 25(2), 98-104 (2004).
175. Barnes D, Kunitomi M, Vignuzzi M, Saksela K, Andino R. Harnessing endogenous miRNAs to control virus tissue tropism as a strategy for developing attenuated virus vaccines. Cell Host. Microbe 4(3), 239-248 (2008).
176. Wu T, Wieland A, Araki K et al. Temporal expression of microRNA cluster miR-17-92 regulates effector and memory CD8+ T-cell differentiation. Proc. Natl Acad. Sci. USA 109(25), 9965-9970 (2012).
177. Lauring AS, Jones JO, Andino R. Rationalizing the development of live attenuated virus vaccines. Nat. Biotechnol. 28(6), 573-579 (2010).
178. de Vries RP, Smit CH, de Bruin E et al. Glycan-dependent immunogenicity of recombinant soluble trimeric hemagglutinin. J. Virol. 86(21), 11735-11744 (2012).
179. Ekiert DC, Wilson IA. Broadly neutralizing antibodies against influenza virus and prospects for universal therapies. Curr. Opin. Virol. 2(2), 134-141 (2012).